On the Progression From Early-to Late-Stage Melanoma: A Potential Sequence of Molecular Events Using Data From Droplet Digital PCR and Array Comparative Genomic Hybridization, A Pilot Study.

IF 0.8 4区 医学 Q4 DERMATOLOGY
American Journal of Dermatopathology Pub Date : 2026-11-01 Epub Date: 2026-06-16 DOI:10.1097/DAD.0000000000003350
Jason R McFadden, Arkar Htoo, Advaita S Chaudhari, Mirjana Stevanovic, Gregory J Tsongalis, Edward G Hughes, Aravindhan Sriharan
{"title":"On the Progression From Early-to Late-Stage Melanoma: A Potential Sequence of Molecular Events Using Data From Droplet Digital PCR and Array Comparative Genomic Hybridization, A Pilot Study.","authors":"Jason R McFadden, Arkar Htoo, Advaita S Chaudhari, Mirjana Stevanovic, Gregory J Tsongalis, Edward G Hughes, Aravindhan Sriharan","doi":"10.1097/DAD.0000000000003350","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Melanoma progression is generally associated with a stepwise increase in genomic complexity. Although the copy number variations (CNVs) known to occur in melanoma are well characterized, the order in which they accumulate during melanomagenesis remains incompletely understood. To explore this, we used droplet digital polymerase chain reaction to calculate absolute copy numbers of RREB1 and CDKN2A , the most commonly amplified and deleted genes in melanoma, in 51 formalin-fixed, paraffin-embedded melanomas. Each sample also underwent chromosomal microarray analysis to determine its CNV burden, which we graded according to the number of the following melanoma-associated CNVs present: RREB1 gain, CDKN2A loss, MYC gain, and MYB loss. In this pilot study, increasing CNV burden was associated with a gradual increase in average RREB1 copy number: from 2.00 in CNV-negative melanomas to 2.68 in melanomas with isolated RREB1 gain; 2.75 in melanomas with RREB1 gain and CDKN2A loss; 2.93 in melanomas with RREB1 gain and MYC gain; and 3.23 in melanomas with RREB1 gain, CDKN2A loss, and MYC gain ( F = 10.43, P < 0.001). A parallel trend was observed for average CDKN2A copy number, which decreased progressively with increasing CNV burden: from 2.02 in CNV-negative melanomas to 1.33 in melanomas with isolated CDKN2A loss; 1.15 in melanomas with CDKN2A loss and MYC gain; and 0.53 in melanomas with CDKN2A loss and MYB loss ( F = 12.01, P < 0.001). These findings support a potential model of stepwise CNV accumulation in melanoma: early RREB1 gain and/or CDKN2A loss, followed by MYC gain, and ultimately MYB loss.</p>","PeriodicalId":50967,"journal":{"name":"American Journal of Dermatopathology","volume":" ","pages":"853-859"},"PeriodicalIF":0.8000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Dermatopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DAD.0000000000003350","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Melanoma progression is generally associated with a stepwise increase in genomic complexity. Although the copy number variations (CNVs) known to occur in melanoma are well characterized, the order in which they accumulate during melanomagenesis remains incompletely understood. To explore this, we used droplet digital polymerase chain reaction to calculate absolute copy numbers of RREB1 and CDKN2A , the most commonly amplified and deleted genes in melanoma, in 51 formalin-fixed, paraffin-embedded melanomas. Each sample also underwent chromosomal microarray analysis to determine its CNV burden, which we graded according to the number of the following melanoma-associated CNVs present: RREB1 gain, CDKN2A loss, MYC gain, and MYB loss. In this pilot study, increasing CNV burden was associated with a gradual increase in average RREB1 copy number: from 2.00 in CNV-negative melanomas to 2.68 in melanomas with isolated RREB1 gain; 2.75 in melanomas with RREB1 gain and CDKN2A loss; 2.93 in melanomas with RREB1 gain and MYC gain; and 3.23 in melanomas with RREB1 gain, CDKN2A loss, and MYC gain ( F = 10.43, P < 0.001). A parallel trend was observed for average CDKN2A copy number, which decreased progressively with increasing CNV burden: from 2.02 in CNV-negative melanomas to 1.33 in melanomas with isolated CDKN2A loss; 1.15 in melanomas with CDKN2A loss and MYC gain; and 0.53 in melanomas with CDKN2A loss and MYB loss ( F = 12.01, P < 0.001). These findings support a potential model of stepwise CNV accumulation in melanoma: early RREB1 gain and/or CDKN2A loss, followed by MYC gain, and ultimately MYB loss.

从早期到晚期黑色素瘤的进展:利用液滴数字PCR和阵列比较基因组杂交数据的潜在分子事件序列,一项初步研究。
摘要:黑色素瘤的进展通常与基因组复杂性的逐步增加有关。虽然已知黑色素瘤中发生的拷贝数变异(CNVs)已经被很好地表征,但它们在黑色素瘤形成过程中积累的顺序仍然不完全清楚。为了探讨这一点,我们使用液滴数字聚合酶链反应计算了51个福尔马林固定石蜡包埋的黑色素瘤中,黑色素瘤中最常扩增和缺失的基因RREB1和CDKN2A的绝对拷贝数。每个样本还进行了染色体微阵列分析,以确定其CNV负荷,我们根据以下黑色素瘤相关CNV的数量进行分级:RREB1增加、CDKN2A缺失、MYC增加和MYB缺失。在这项初步研究中,CNV负担的增加与RREB1平均拷贝数的逐渐增加相关:从CNV阴性黑色素瘤的2.00增加到具有分离性RREB1增益的黑色素瘤的2.68;在RREB1获得和CDKN2A缺失的黑色素瘤中为2.75;伴有RREB1和MYC增益的黑色素瘤患者为2.93;在RREB1增加、CDKN2A缺失和MYC增加的黑色素瘤中为3.23 (F = 10.43, P < 0.001)。CDKN2A的平均拷贝数也有类似的趋势,随着CNV负荷的增加,CDKN2A的平均拷贝数逐渐下降:从CNV阴性黑色素瘤的2.02降至CDKN2A分离缺失的黑色素瘤的1.33;CDKN2A缺失和MYC增加的黑色素瘤1.15;CDKN2A缺失和MYB缺失的黑色素瘤为0.53 (F = 12.01, P < 0.001)。这些发现支持了黑色素瘤中CNV逐步积累的潜在模型:早期RREB1获得和/或CDKN2A丢失,随后MYC获得,最终MYB丢失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
9.10%
发文量
453
审稿时长
3 months
期刊介绍: The American Journal of Dermatopathology offers outstanding coverage of the latest diagnostic approaches and laboratory techniques, as well as insights into contemporary social, legal, and ethical concerns. Each issue features review articles on clinical, technical, and basic science advances and illuminating, detailed case reports. With the The American Journal of Dermatopathology you''ll be able to: -Incorporate step-by-step coverage of new or difficult-to-diagnose conditions from their earliest histopathologic signs to confirmatory immunohistochemical and molecular studies. -Apply the latest basic science findings and clinical approaches to your work right away. -Tap into the skills and expertise of your peers and colleagues the world over peer-reviewed original articles, "Extraordinary cases reports", coverage of practical guidelines, and graphic presentations. -Expand your horizons through the Journal''s idea-generating forum for debating controversial issues and learning from preeminent researchers and clinicians
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书